GlaxoSmithKline has agreed to sell two meningitis vaccines to Pfizer to satisfy antitrust concerns after its recent acquisition of vaccines business of Novartis.
The British drugmaker said on Monday that the total consideration for the sale of its Nimenrix and Mencevax products to Pfizer’s Irish unit, including some deferred payments, was 115 million euros.
GSK agreed to sell the two older vaccines, which are marketed outside the United States and had combined sales last year of 34 million pounds ($54 million), to meet concerns raised by the European Commission and other antitrust regulators.
Meningitis vaccines were an issue for competition authorities because GSK acquired two rival products from Novartis, known as Menveo and Bexsero.
The sale to Pfizer is expected to be completed before the end of the year.
Full content: Business Finance News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Major App Developers Shun Apple’s New Payment Options, Citing Unfavorable Fees
May 12, 2024 by
CPI
Ex-Contractor Pleads Guilty to Rigging Bids in Wildfire Fuel Services for US Forest Service
May 12, 2024 by
CPI
UK Newspapers Warn Apple Against “Web Eraser” Feature’s Threat to Journalism
May 12, 2024 by
CPI
Microsoft Ordered to Pay $242 Million in Patent Infringement Case
May 12, 2024 by
CPI
UK Antitrust Authority Launches Formal Probe into Olink’s Sale to Thermo Fisher
May 12, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI